Pfizer (NYSE:PFE) shares rise 3.6% on dividend strength as analyst forecasts remain unchanged
Pfizer Inc. rose 3.6% last week, outperforming the S&P 500 by 5.2 percentage points. Shares finished Friday at $25.05.
Pfizer (NYSE:PFE) yield math back in focus after cancer drug miss, shares recover Friday
U.S. cash stock trading was closed Sunday. The New York Stock Exchange posts regular hours of 9:30 a.m. to 4:00 p.m. ET, and says its next holiday for 2026 is Independence Day, observed Friday, July 3. Pfizer’s last trade was Friday’s close.
Pfizer trades up with Rigel’s Veppanu deal done
Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed.
Pfizer Faces Busy Week After Friday’s Drop
Pfizer Inc. is starting the week stuck after shares fell Friday. Investors have yet to see if a better quarter is enough for ongoing growth. With U.S. markets shut over the weekend, PFE last traded at $25.33 on Friday.
Pfizer Stock Rebound Bet: Why the Beaten-Down Healthcare Giant Is Back in Focus
Pfizer stock picked up 1.5% to hit $26.07 as of 10:58 a.m. EDT on Monday, bringing the company’s market value to roughly $149 billion. Investors seem willing to revisit the name after a steep drop from its COVID-era highs, with attention zeroing in on three main issues: looming patent expirations, a late-stage push into the GLP-1 weight-loss drug market, and whether Pfizer has enough cash to keep its dividend intact.
Pfizer Stock Price Today: PFE Falls 1.6% but Stays Near 52-Week High (MarketWatch)
Pfizer ended Thursday down 1.6% at $26.86, caught up in a sweeping selloff across U.S. equities. Oil prices jumped on intensifying Middle East tensions, and the slide hit all three major indexes—S&P 500, Dow, and Nasdaq—each losing over 1.5%.
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now
Pfizer slipped 0.3% to $27.52 ahead of the bell Wednesday, following a 2.1% gain Tuesday that took shares to $27.61. The stock hit $27.73 during the session, with trading volume reaching roughly 43.6 million shares.
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook
Pfizer shares climbed 0.8% to $27.01 by 12:43 p.m. EST, building on a rebound after a volatile stretch triggered by fresh trial data and a quarterly earnings report.
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom
Novavax shares ended Friday at $8.85, slipping roughly 6.4% during the session. U.S. markets remain closed over the weekend and will open again Monday.
Pfizer stock edges up as traders brace for Feb. 3 earnings and a Fed decision
Pfizer shares climbed 0.7% to $25.84 in afternoon trading Monday, bouncing between $25.60 and $25.89 earlier. The stock had closed at $25.65 previously.
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts
Pfizer shares ended Thursday up 0.8%, closing at $26.10 after climbing Wednesday. The stock stayed comfortably within the mid-$20s, fluctuating between $25.75 and $26.31 during the session.
Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus
Pfizer shares climbed Thursday after the company announced two deals highlighting its strategy to transform its business. By afternoon, the stock had gained roughly 0.8%, reaching $26.10.
Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus
Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session.
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”
Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.
Pfizer stock today: PFE ends first 2026 session higher as pricing scrutiny returns and Feb. 3 results loom
Pfizer Inc shares last closed up 1.1% at $25.18 on Friday, after a weak finish to 2025. U.S. markets were closed on Saturday.
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes
Pfizer Inc shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including a 15% rise for its COVID-19 shot Comirnaty — as drugmakers overall line up price increases on at least 350 branded medicines, with a median hike of about 4%. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital, while Pfizer said its average increase for innovative medicines and vaccines would be below inflation. Reuters
Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes
Pfizer Inc shares were last indicated slightly lower after hours on Wednesday after a report said the drugmaker plans to raise U.S. list prices on about 80 medicines in 2026. U.S. stock markets were closed on Thursday for the New Year’s Day holiday.
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight
Pfizer Inc. shares fell about 0.4% to $24.90 in after-hours trading on Wednesday, after a report said the drugmaker is leading a wave of U.S. list-price increases set for 2026. The data, compiled by healthcare research firm 3 Axis Advisors, showed drugmakers plan hikes on at least 350 branded medicines, with Pfizer accounting for around 80 increases, including a 15% rise for its COVID vaccine Comirnaty. “They really just nibble around the margins,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston. Reuters
Pfizer stock today: PFE slips after report on 2026 U.S. drug price hikes
Pfizer shares were down 0.1% at $24.96 in afternoon trade on Wednesday after a Reuters report said the drugmaker plans U.S. list-price hikes on about 80 medicines in 2026. Reuters
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook
Pfizer Inc shares were up about 0.1% at $25.03 in afternoon trading on Tuesday, after moving between $24.92 and $25.10. TD Cowen reiterated its Hold rating and kept a $30 price target, pointing to negative trends in its model through 2030 despite the stock’s dividend yield near 7%. Investing.com
TechStock² Updates
